Nephrocare Health Services Limited filed a regulatory disclosure pursuant to Regulation 30 of SEBI Listing Regulations regarding the allotment of equity shares under its employee stock option plan.

The Nomination and Remuneration Committee approved the allotment via circular resolution on July 14, 2026. The company allotted 218,297 equity shares of face value ₹2 each, fully paid-up, to eligible employees who exercised stock options under the ESOP Scheme 2011. These shares will rank pari-passu with existing equity shares in all respects.

Capital Structure Impact

  • Pre-allotment issued, subscribed and paid-up equity share capital: ₹20,06,81,434 comprising 10,03,40,717 equity shares of ₹2 each
  • Post-allotment issued, subscribed and paid-up equity share capital: ₹20,11,18,028 comprising 10,05,59,014 equity shares of ₹2 each
  • Increase in share capital: ₹4,36,594

Regulatory Approvals

The company has obtained in-principle listing approvals for these shares:

  • National Stock Exchange of India Limited: Letter no. NSE/LIST/54518 dated May 11, 2026
  • BSE Limited: Letter no. DCS/ESOP/IP/RD/062/2026-27 dated May 11, 2026

Financial Details

Total money realized from exercise of options: ₹2,08,18,944.35 (excluding applicable taxes)

The exercise involved multiple tranches with varying exercise prices and premiums as detailed in Annexure C, ranging from:

  • Exercise prices: ₹49.2667 to ₹246.5990 per share
  • Premium per share: ₹47.2667 to ₹244.5990
  • Number of shares per tranche: 775 to 105,000

Share Details

  • Face value: ₹2 per share
  • Distinctive numbers: 10,03,40,718 to 10,05,59,014 (both inclusive)
  • No lock-in restrictions apply
  • Shares are identical to existing shares in all respects

Scheme Background

The ESOP Scheme 2011 was originally structured such that each option entitled the holder to subscribe to one equity share of ₹10 face value. However, due to corporate actions including:

1. Sub-division of every equity share of ₹10 face value into five equity shares of ₹2 face value (approved May 26, 2025)

2. Bonus issue in ratio of 1:2 (two bonus shares for every one equity share held, approved May 26, 2025)

The outstanding stock options were adjusted to preserve value. Consequently, each original stock option became exercisable into fifteen equity shares of ₹2 face value, with exercise prices correspondingly adjusted.

The diluted earnings per share will be computed in accordance with Indian Accounting Standards (Ind AS 33 - Earnings per Share) after giving effect to this allotment.

The information has been made available on the company's website at www.nephroplus.com.